ESC 2026: enlicitide extends oral PCSK9 benefits beyond LDL-C lowering

Phase 3positiveLipfendraPositive

AI Analysis

Summary

MSD presented Phase III data for enlicitide (Lipfendra) at ESC 2026 demonstrating the oral PCSK9 inhibitor's efficacy in lowering Lp(a) levels beyond LDL-C reduction benefits.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III data demonstrated Lp(a)-lowering efficacy beyond LDL-C lowering

Importance:6/10

Sentiment:

0.70

PCSK9 inhibitorLp(a) loweringLDL-CESC 2026oral therapy

Related Companies

$MRK

Read the original article

Published by Clinical Trials Arena on August 28, 2026 4:06 PM

Read Original